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About one-fifth of patients treated with levothyroxine have serum thyrotropin (TSH) above 
target concentrations but, in approximately 15% of them, the cause of this TSH insuf-
ficient normalization remains unknown. We report the cases of two regularly menstru-
ating women with known thyroid disease who had TSH levels consistently >3 mU/L 
(and sometimes above target levels) during mid-cycle, but consistently lower serum 
levels during the follicular and luteal phases of menstrual cycle. A major TSH release by 
the thyrotrophs in response to high circulating levels of estradiol (E2) at mid-cycle may 
increase levels of TSH compared to other phases of the cycle. The increased TSH can 
be misinterpreted as refractory hypothyroidism if the woman is under L-T4 replacement 
therapy or as subclinical hypothyroidism if the woman is not. Our findings might have 
important implications for diagnosis and management of thyroid disease, suggesting to 
request serum TSH measurements outside of the periovulatory days.
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INtRoDUCtIoN
Approximately 20% of levothyroxine-treated patients have serum thyrotropin (TSH) above target 
level (1, 2). The ensuing biochemical and instrumental diagnostic work-up is multidisciplinary, can 
require hospitalization and be expensive. Yet, the cause of serum TSH insufficient normalization 
remains unknown in approximately 15% of patients (1).
A fortuitous circumstance, which occurred in the first patient reported here, led to the hypothesis 
that a robust TSH release by the thyrotrophs in response to high circulating levels of estradiol (E2) 
at mid-cycle may increase levels of TSH compared to other phases of the cycle. We report the two 
patients, because they could represent the classic tip of the iceberg.
BaCKGRoUND
The two women, aged 30 and 32 years, had primary hypothyroidism associated with Hashimoto’s 
thyroiditis, for which they were treated with approximately 1.5  μg/kg body weight/day levo-
thyroxine by the endocrinologists who had observed the patients for the first time. Over the 
approximately 3 years of levothyroxine replacement therapy, both patients were always sampled 
between 8:00 and 8:30 a.m. in the same laboratory. The patients had no symptoms during L-T4 
therapy; only patient A referred mild asthenia, but lower than in the pretherapy period. We 
excluded causes of elevated TSH in the face of levothyroxine therapy based on the extensive 
FIGURe 1 | Changes of estradiol (E2), luteinizing hormone (LH), prolactin (PRL), and thyrotropin (TSH) in the two women, during the menstrual cycle. Arrows 
indicate TSH levels that were measured at the same time when the other hormones were also measured. The total number of menstrual cycles during which TSH 
levels were measured are nine for patients A and five for patients B. In our laboratory, follicular, midcycle, and luteal phase serum E2 ranges 23–139, 83–495, and 
42–338 pg/mL (chemiluminescent assay by Beckman Coulter).
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taBle 1 | Thyrotropin (TSH) and FT4 levels in the two women over the 37 or 
34 menstrual cycles following initiation of L-T4 therapy, based on the day of the 
menstrual cycle.a
Mentrual cycle 
since the 
beginning of 
l-t4 therapy
Corresponding 
day of the cycle
Corresponding 
tsH level, mU/l
Corresponding 
Ft4 level, ng/dl
Case A 2nd 2nd 2.0
6th 28th 2.4
11th 17th 3.9
17th 8th 2.3 1.4 (0.7–1.8)
21st 24th 2.8
25th 13th 4.2
31st 26th 1.75 1.45 (0.7–1.8)
36th 14th 4.6 1.4 (0.7–1.8)
21st 2.9
37th 4th 2.6
Case B 3rd 5th 2.8
15th 13th 3.75
29th 15th 5.1 1.33 (0.9–1.6)
33rd 16th 4.7
27th 2.8
34th 6th 2.6
aPrior to L-T4 therapy, in patient A, TSH was 19.7 mU/L in mid-cycle with FT4  
0.63 ng/dL (0.7–1.48) but TSH was 13.2 mU/L in early follicular phase with FT4 
0.65 ng/dL. In patient B, TSH was 27.4 mU/L in mid-cycle with FT4  
0.78 ng/dL (0.9–1.6). In the laboratory, TSH normal range was 0.27 4.0 mU/L.
diagnostic work-up described previously (1). Particularly, non-
compliance and pharmacological interference on the intestinal 
absorption of L-T4 were excluded by accurate medical history. 
Gastrointestinal diseases were excluded by the urea breath test 
for H. pylori infection, by measuring serum parietal cells anti-
bodies (Ab), antitransglutaminase Ab and anti endomysium 
Ab. Furthermore, both women did not take any other drugs 
and they did not have gastrointestinal diseases.
Once we suspected the possibility of elevated serum TSH 
triggered by the elevation of serum E2 around midcycle, 
we also measured E2, prolactin (PRL) and gonadotropins 
[follicle-stimulating hormone (FSH) and luteinizing hormone 
(LH)].
The suspicion was fortuitous (see below, patient A) because, 
to obtain data on certain hormones assayed on days 1–7 of the 
follicular phase, we started recruiting regularly menstruating 
women with known thyroid disease.
Patient A postponed sampling for the reproductive hormone 
assay because she wished to combine it with the TSH assay. 
A posteriori, this day of TSH sampling was mid-cycle, as she men-
struated 13 days earlier and 15 days later. Serum TSH (4.6 mU/L) 
was the highest value recorded. Because of her regular menses 
(27- to 29-day duration), we easily matched her previous TSH 
assays with her menstrual cycle days (Figure 1). TSH levels and 
sometimes also FT4 levels were measured in several days of nine 
different menstrual cycles (Table  1). Serum E2, PRL, FSH and 
LH were also measured in the ovulatory and luteal phases of the 
36th cycle and follicular phase of the 37th cycle (as indicated by 
the arrows in Figure 1). Serum TSH was <3.0 mU/L in both the 
luteal and follicular phase. Prior to levothyroxine therapy, TSH 
was 19.7 mU/L (mid-cycle), but it was 13.2 mU/L upon repeating 
the assay 19 days later (early follicular phase) to have confirma-
tion of elevated TSH.
Based on patient A, we wished to confirm these observa-
tions in another woman (patient B, Figure  1) in whom the 
diagnostic work-up for apparently undertreated hypothyroid-
ism (1) had been inconclusive. Again, matching the days of 
blood sampling with the days of her regular menstrual cycle 
(Table  1), the two highest TSH values coincided with mid-
cycle (Figure 1). Evaluated prospectively (as indicated by the 
arrows in Figure  1), the pattern held. The total number of 
menstrual cycles during which TSH levels were measured was 
five for patient B (Table 1).
In summary, except for the aforementioned peak values at 
mid-cycle, in the two women post-therapy serum TSH had been 
<3.0  mU/L when they were sampled between the 3rd–10th or 
the 20th–26th day of menstrual cycle, but it was greater when 
sampled in the periovulatory days.
DIsCUssIoN
To the best of our knowledge, we are unaware of cases similar 
to the two we are reporting here. In both patients, the highest 
TSH levels coincided with the highest levels of both estradiol 
(>300  pg/mL) and PRL, a well-known estrogen-upregulated 
hormone. Such estrogen dependency of serum TSH in the two 
women agrees with data of the literature (1, 3–8). These data are 
(i) the progressively increasing serum levels of TSH during gesta-
tion; (ii) the greater serum TSH levels in women with polycystic 
ovary syndrome or in women taking estroprogestins compared 
to control women, and in reproductive age women compared 
to men; (iii) the increased daily requirement of levothyroxine 
during endogenous or exogenous hyperestrogenism. Even in 
euthyroid postmenopausal women under estrogen therapy, 
serum TSH increased compared to pretherapy levels (5). In this 
study (5), in addition to 25 postmenopausal hypothyroid women 
(18/25 under levothyroxine replacement therapy), 11 euthyroid 
postmenopausal women were investigated. All women received 
conjugated estrogens in a daily oral dose of 0.625 mg for 48 weeks. 
Though in the euthyroid group pre-estrogen therapy serum 
TSH levels (1.3 ± 0.6 m/UL) were reported to be insignificantly 
changed over the 48 weeks of estrogen therapy, all post-therapy 
TSH levels, starting from the sixth week, were above baseline 
levels, approached or reached (48th week) 2.0  mU/L (5). In 
the hypothyroid group, serum TSH increased from 0.9 ± 1.1 to 
3.2 ±  3.1  mU/L (P <  0.001), with levels greater than 7  mU/L 
in 7 of the 18 women (39%) under levothyroxine-replacement 
therapy (5).
Since it is known (9) that the thyrotrops have estrogen recep-
tors, though not as abundant as other anterior pituitary cell 
types, and in view of literature on TSH responsiveness to E2 
(10–12), we can elaborate a hypothesis for our findings in the 
two patients.
In ovariectomized rats, increasing serum estrogen levels within 
the physiological range increase both basal and TRH-stimulated 
TSH release as well as PRL release (10, 11). We hypothesize that 
a robust E2-driven TSH release at mid-cycle with consequent 
elevation of serum TSH may result from either a robust circulating 
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E2 peak and associated hyper-response of the E2 receptors in 
the thyrotrops or increased sensitivity of E2 receptors to less 
robust circulating E2 levels. However, additional mechanism 
cannot be excluded. These mechanisms include the E2-driven 
(i) inhibition of the negative feedback that thyroid hormones exert 
on both basal and TRH-stimulated TSH release (12), (ii) induc-
tion of TRH receptors in the pituitary (13), and (iii) decreased 
TRH degradation (14).
CoNClUDING ReMaRKs
In conclusion, a large prospective study is required to know the 
proportion of reproductive age women, under L-T4 replacement 
therapy, with elevation of serum TSH due to mid-cycle blood 
sampling. Once confirmed, our observations may have important 
implications for diagnosis and management of thyroid disease, 
and may call for standardization of serum TSH measurement 
outside of periovulatory days.
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